ClinicalTrials.gg
RecruitingNCT06309563AMINOBUpdated Mar 31, 2026

Metabolic Effects of a Diet Replaced With Essential Amino Acids

An interventional study of Aminoacid supplementation and Placebo in Obesity Morbid and Weight Loss, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Open to participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Istituto Auxologico Italiano · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Aug 2023, registered Mar 2024).
  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Obesity, Morbid with a site in Italy — 11 open to participants now, 12 under way, none of them phase 3. Obesity, Morbid · Italy.

Planned enrollment
14th of 25
60 · median 80
Started
2023
with 3 others
No phase
22 of 54
8 open now
Primary completion
2026-12
later than 6 of 11 live
Registered
49th of 54
by date
Lead sponsor
5 of 54
Istituto Auxologico Italiano

Among the 54 studies in Obesity, Morbid with a site in Italy, this one is the 14th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2023, is one of 22 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 49th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

11 of the 54 studies in Obesity, Morbid with a site in Italy are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 45 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Obesity, Morbid with a site in Italy, or all of them as a file.
02

Study summary

The effectiveness of low-protein diets supplemented with essential aminoacid (EAA) formulas in genetic disorders of amino acid (AA) catabolism, such as maple syrup urine disease (MSUD), is widely recognized (Blackburn PR et al. 2017). The main aim of the present study is to evaluate a difference in the effectiveness of a multidisciplinary rehabilitation program in patients with high degree of obesity with and without supplementation of this new formula of amino acids (essential + tricarboxylic acids - EAA-AC). For this reason, patients of both sexes, aged between 45 and 65, suffering from high-grade obesity will be recruited in Piancavallo. The enrolled patients divided, randomly, into two groups will be given: EAA-AC group a low-calorie and low-protein diet integrated with 4 sachets of EAA-AC supplement per day; the control group will follow a low-calorie and low-protein diet only with placebo. The parameters considered, after two weeks of treatment, will be: weight loss; the maintenance/recovery of muscle mass assessed through changes in body composition and functional tests (Hand grip, 6MWT or TUG) but also through the analysis of mitochondrial function in PBMC and circulating levels of mtDNA; the improvement of the glucose picture and the lipid profile.

1 month after discharge, patients will carry out an outpatient check-up to evaluate the maintenance of muscle mass using impedance testing.

03

Conditions studied

  • Obesity Morbid
  • Weight Loss

Keywords

  • Muscle mass during weight loss
04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Obesity ( >35kg/m2)

Exclusion criteria

Exclusion Criteria:

  • Type 2 diabetes mellitus
  • Renal failure
  • Heart failure ( NYHA, class IV)
  • Liver cirrhosis
  • Neoplasms
  • Muscular or non-autonomic pathologies
  • Neurological-neurodegenerative pathologies
  • Cognitive decline
  • Non-menopausal women.
  • Patients who have undergone bariatric surgery in the previous 12 months
  • Patients on pharmacological treatment for weight loss in the last three weeks
  • Patients using vitamin and amino acid supplements in the last three weeks
  • Patients on hormone therapy (e.g. L-thyroxine, testosterone).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Aminoacids

    Patients with obesity treated with essential aminoacids (EAA-AC)

    Dietary Supplement: Aminoacid supplementation

  • Placebo comparator
    Control

    Patients with obesity treated with placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementAminoacid supplementation

    Low-calorie and low-protein diet + with 4 sachets of EEA-AC supplement per day for 2 weeks

    Also known as: EAA-AC, Controls

  • Dietary supplementPlacebo

    Low-calorie and low-protein diet + placebo for 2 weeks

06

What researchers measure

Primary outcomes

  1. Muscle mass

    Change in muscle mass during weight loss assessed through changes in body composition

    Time frame: At baseline and at 2 weeks after start of intervention

Secondary outcomes

  1. 6 minute walking test (6MWT)

    Change in distance covered in 6 minutes of walking during weight loss

    Time frame: At baseline and at 2 weeks after start of intervention

07

Study locations

1 of 1 sites recruiting
  • Istituto Auxologico Italiano, Site Piancavallo
    Oggebbio, Verbania 28921, Italy
    Recruiting
08

References and documents

Publications

  • Nisoli E, Falcone S, Tonello C, Cozzi V, Palomba L, Fiorani M, Pisconti A, Brunelli S, Cardile A, Francolini M, Cantoni O, Carruba MO, Moncada S, Clementi E. Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16507-12. doi: 10.1073/pnas.0405432101. Epub 2004 Nov 15. PubMed 15545607 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 40 months after the start.

Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 40 months is above that.

Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2024
First posted
Mar 13, 2024
StartActual
Aug 30, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06309563
Responsible party
Sponsor
First posted
Mar 13, 2024
Start date
Aug 30, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 31, 2026

Study contacts

Amelia Brunani, MD
Contact
brunani@auxologico.it
390323514232

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion